Grant of PDMR Options

RNS Number : 1423N
Instem plc
28 September 2021
 

Instem plc

 

("Instem", the "Company")

 

Grant of PDMR Options

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that Phil Reason (Chief Executive Officer) and Nigel Goldsmith (Chief Financial Officer) have each been granted awards of nil-cost options over 25,000 Ordinary Shares under the Instem plc 2018 Long Term Incentive Plan ("LTIP").  These options will ordinarily vest and become exercisable in 2024 pursuant to the rules of the LTIP and are subject to meeting share price targets.

After these grants of options, Mr Reason and Mr Goldsmith hold options over a total of 208,816 and 279,531 Ordinary Shares, respectively. 

For further information, please contact:

 

Instem plc

 Via Walbrook

Phil Reason, CEO


Nigel Goldsmith, CFO




Singer Capital Markets (Nominated Adviser & Broker)

 +44 (0) 20 7496 3000

Peter Steel, Alex Bond, Daniel Dearden-Williams (Corporate Finance)


Rachel Hayes (Corporate Broking)




Walbrook Financial PR

 +44 (0) 20 7933 8780

Tom Cooper

iinstem@walbrookpr.com

Nick Rome


Nicholas Johnson


 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

 Phil Reason

2

Reason for the notification

a)

 

Position/status

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Grant of nil cost options under the Company's LTIP



Identification code

GB00B3TQCK30



b)

 

Nature of the transaction


Grant of nil cost options under the Company's LTIP

 

c)

 

Price(s) and volume(s)







Price

Volume(s)




Nil

25,000







d)

 

Aggregated information




- Aggregated volume

N/A - Single transaction



- Price




e)

 

Date of the transaction

27 September 2021

f)

Place of the transaction

Off-market transaction

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

 

 Nigel Goldsmith

2

Reason for the notification

a)

 

Position/status

Chief Financial Officer

b)

 

Initial notification /Amendment

Initial

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

 

Instem plc

b)

 

LEI

 

 

213800PILYUFNNROQX68

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10p each



Identification code

GB00B3TQCK30



b)

 

Nature of the transaction

Grant of nil cost options under the Company's LTIP

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




Nil

25,000







d)

 

Aggregated information

N/A - Single Transaction



- Aggregated volume




- Price




e)

 

Date of the transaction

27 September 2021

f)

Place of the transaction

Off-market transaction

 

 

 

 

 

 

About Instem

 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration and Informatics-based Insight Generation.

 

Instem solutions are in use by over 700 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.

 

To learn more about Instem solutions and its mission, please visit  www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKOBQBBKBDCB

Companies

Instem (INS)
UK 100

Latest directors dealings